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ANO5 mutations in the polish limb 
girdle muscular dystrophy patients: 
Effects on the protein structure
Adam Jarmula  1, Anna Łusakowska2, Jakub P. fichna3, Malgorzata topolewska4, 
Anna Macias2, Katherine Johnson5, Ana töpf5, Volker Straub5, edyta Rosiak  6, 
Krzysztof Szczepaniak7, Stanisław Dunin-Horkawicz7, Aleksandra Maruszak3, 
Anna M. Kaminska2 & Maria Jolanta Redowicz4
LGMD2L is a subtype of limb-girdle muscular dystrophy (LGMD), caused by recessive mutations 
in ANO5, encoding anoctamin-5 (ANO5). We present the analysis of five patients with skeletal 
muscle weakness for whom heterozygous mutations within ANO5 were identified by whole exome 
sequencing (WES). Patients varied in the age of the disease onset (from 22 to 38 years) and severity 
of the morphological and clinical phenotypes. Out of the nine detected mutations one was novel 
(missense p.Lys132Met, accompanied by p.His841Asp) and one was not yet characterized in the 
literature (nonsense, p.Trp401Ter, accompanied by p.Asp81Gly). The p.Asp81Gly mutation was also 
identified in another patient carrying a p.Arg758Cys mutation as well. Also, a c.191dupA frameshift 
(p.Asn64LysfsTer15), the first described and common mutation was identified. Mutations were 
predicted by in silico tools to have damaging effects and are likely pathogenic according to criteria 
of the American College of Medical Genetics and Genomics (ACMG). Indeed, molecular modeling of 
mutations revealed substantial changes in ANO5 conformation that could affect the protein structure 
and function. In addition, variants in other genes associated with muscle pathology were identified, 
possibly affecting the disease progress. The presented data indicate that the identified ANO5 mutations 
contribute to the observed muscle pathology and broaden the genetic spectrum of LGMD myopathies.
Limb-girdle muscular dystrophies (LGMD) form a group of inherited myopathies showing progressive 
limb-girdle weakness with sparing of the facial and distal muscles. According to the inheritance mode, LGMD is 
classified into two general categories: autosomal dominant (LGMD1) and autosomal recessive (LGMD2) forms. 
So far, 33 genes have been associated with the disease, nine dominant and 26 recessive1–3. Molecular pathophys-
iology and therefore clinical phenotypes of the LGMDs are highly heterogeneous as the mechanisms of disease 
include defects in numerous proteins1,4. The observation that mutations within the same gene could be associated 
with variable phenotypes was made for numerous LGMD associated genes, including desmin and dysferlin1,4–8. It 
is noteworthy that variable symptoms are often observed even within a family with the same causative mutation, 
indicating that a primary pathogenic variant combined with potentially modifying variants may exacerbate or 
mitigate the phenotype (for example9).
The LGMD2L subtype is associated with mutations in the anoctamin-5 gene (ANO5). ANO5 is localized to 
chr11p14.3, spans 90,192 bp and contains 22 exons. The gene encodes anoctamin-5 (ANO5), a ~100-kDa protein 
composed of 913 amino acids, containing eight transmembrane domains10,11. The protein belongs to a family of 
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at least ten proteins (ANO1-10) involved in a variety of cellular functions such as ion transport, phospholipid 
scrambling, and regulation of other membrane proteins12,13. While ANO1, ANO2, ANO6, ANO8, and ANO9 were 
found to code for calcium-activated chloride channels (CaCC), an exact function of ANO5 still remains elusive. 
Currently ANO5 is believed to be engaged in processes related to muscle membrane repair and ion transport12,13. 
ANO5 localizes to the endoplasmic reticulum (ER) where it is postulated to function as an intracellular channel14. 
In addition, ANO5 is highly expressed in cardiac and skeletal muscle as well as in chondrocytes and osteoblasts, 
suggesting its important role(s) in the musculoskeletal system15.
The still-expanding spectrum of ANO5-related clinical phenotypes is highly variable. Although the majority 
of known mutations are recessive and cause muscle disease, rare autosomal dominant ANO5 mutations cause a 
totally different clinical entity, gnathodiaphyseal dysplasia (GDD)14–16. Moreover, the recent study linked dental 
tumor (giant cementoma) to an autosomal dominant mutation in ANO5 associated with gnathodiaphyseal dys-
plasia17. The functional differences between dominant and recessive ANO5 mutations are not yet fully understood 
although there is a report indicating that homodimer formation or interaction with other anoctamin isoforms 
could be considered17. The muscle phenotype ranges from asymptomatic hyperCKemia and exercise-induced 
myalgia to proximal and/or distal weakness. The most typical presentation is LGMD2L, diagnosed world-wide 
and is one of the most frequent in Northern Europe encompassing 10–20% of LGMD cases6,9,18. Miyoshi-like dis-
ease or Miyoshi muscular dystrophy 3 (MMD3), also caused by recessive mutations in ANO5, is less common19.
LGMD2L is characterized generally by asymmetric muscle involvement with prevalent quadriceps, biceps 
brachii atrophy, and pain following exercise. The disease onset is in adulthood and the patients are usually ambu-
lant6. There are numerous mutations identified within ANO5 and many of them are localized to the exons coding 
for the cytoplasmically-localized domains, predominantly at the 299 amino acid-long N-terminal segment9,20. 
The first described and most common mutation described so far is c.191dupA (p.Asn64LysfsTer15) in exon 5, 
most probably due to a founder effect9,17,21,22.
In the study presented herein, we address the mechanisms of clinical variability of ANO5-associated muscular 
dystrophies. Thorough analyses of the clinical data of five patients with heterozygous mutations within ANO5 and 
variable phenotypes were performed. Variants identified in two of these patients were already reported in our pre-
vious study23 without addressing the consequences of mutations on the protein structure and clinical phenotype. 
Out of nine identified mutations, three were not reported in databases, p.Lys132Met and p.Trp401Ter, and one, 
p.Tyr23Ter, was only listed in the ExAC database. None of the them was described in literature. Clinical evalua-
tion of the patients (including MRI imaging) and morphological examination of biopsied muscles were aided by 
the molecular dynamics-based structural analysis of the effects of missense mutations on the structure of ANO5 
dimer, the model of which was created for the purpose of this study. Our results indicate that the location of the 
mutation within the polypeptide chain affects the protein structure not only locally, in the vicinity of the mutated 
residue, but also globally, influencing the dimer interface and dynamics, and seemingly the function.
Results
Comprehensive analyses of five patients admitted to the Department of Neurology of the Medical University of 
Warsaw with symptoms of LGMD were carried out; mutations in ANO5 were subsequently identified for each of 
them. The analyses included clinical and electrophysiological evaluation, morphological examination of biopsied 
muscles, MRI of muscles, and genetic analyses including whole exome sequencing (WES). In addition, extensive 
molecular modeling analyses were performed in order to evaluate the potential effects of the identified mutations 
on the ANO5 dimer structure and hence function.
Clinical evaluation. A clinical summary of the examined patients (numbered consecutively 1–5) is presented 
in Table 1. Pedigrees of the probands’ families as well as detailed case descriptions are presented in Supplementary 
Material 1 (parts I and II, respectively). Except for patient 1, family members of other patients were not affected.
Clinical characteristics of all examined patients fulfilled the criteria of limb-girdle muscular dystrophy. All 
patients presented with mild, slowly progressive muscles weakness and/or atrophy, more prominent in the prox-
imal muscles of the lower legs. High creatine kinase (CK) levels (up to 50 times the upper limit), asymmetric 
weakness and myalgia were observed in all cases. The age of onset was in the third or fourth decade, however, the 
first symptoms such as gait disturbances, myalgia, muscle cramps, exercise intolerance or asymmetric weakness 
(of one leg) were variable.
Patients 2 and 3 (males) presented with mild generalized muscle hypertrophy. In two cases (patients 1 and 
5), the posterior compartment of the lower leg muscles was substantially involved. On EMG, myopathic changes 
were detected, however, in two patients (3 and 4) EMG was normal.
Magnetic Resonance Imaging (MRI). MRI examinations were performed for patients 2–5 and are pre-
sented in Fig. 1 and Supplementary Material 2. Patient 1 is deceased and thus could not be examined (see Table 1).
The analysis revealed that patient 2 presented with very severe, symmetric atrophy of the medial head of 
gastrocnemius muscle as opposed to other patients who showed muscle fatty replacement with little volume loss 
or even relative hypertrophy (for details see Supplementary Material 2). Asymmetric changes and fat infiltration 
were visible in the adductor longus muscle at the thigh level (Fig. 1A, arrow), similar to patient 3 (see Fig. 1B). 
However, there was no decrease in muscle bulk. The biopsied left vastus lateralis muscle showed only mild fatty 
degeneration (Fig. 1A, asterisk and arrowhead; and Supplementary Material 2).
In patient 3, muscle fatty degeneration changes in lumbar paraspinal muscles and lower limbs muscles with 
little or no change in the muscle bulk were seen (for details see Supplementary Material 2). At the pelvic level, the 
gluteus minimus muscle was bilaterally severely affected, more than the gluteus medius and maximus muscles. 
Asymmetric muscle changes and fatty degeneration were visible at the thigh level in the adductor longus muscle 
and all heads of the vastus muscle (Fig. 1B, arrow). Mild to moderate symmetric changes were observed in the 
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adductor magnus muscle and hamstrings. In the lower legs, diffuse and severe changes were present in the medial 
head of gastrocnemius muscle and less severe in the lateral head of the gastrocnemius muscle with relative sparing 
of other muscles (Supplementary Material 2). The biopsied left vastus lateralis muscle (Fig. 1B, asteriks) showed 
only very mild fatty changes.
Patient 4 presented with mild fatty degeneration changes in the following muscles of the lower extremities: the 
gluteus muscles, the adductor magnus muscle and hamstrings (see Supplementary Material 2). Moderate fatty 
degeneration were visible in the medial head of the gastrocnemius muscle (Fig. 1C, lower panel, arrows). Also, 
MRI showed little decrease in the volume of the affected muscles. The biopsied left vastus lateralis muscle showed 
no fatty degeneration (Fig. 1C, upper panel, asterisk).
Patient 5 was the only patient in this study who showed abnormalities in the upper limbs with severe fatty 
degeneration and atrophy of the biopsied left biceps brachii muscle (Fig. 1D, upper panel, asterisk and arrow, 
and Supplementary Material 2). Changes in paraspinal muscles were more severe than those in patient 3. At the 
thigh level, the gluteus minimus and medius, adductor magnus and hamstrings were bilaterally severely affected 
with decreased muscle bulk (Supplementary Material 2). Also, some fatty degeneration changes were seen in 
the vastus muscles, similarly to those in patient 3 (Supplementary Material 2). In the lower legs, the patient pre-
sented with severe or complete fatty infiltration and relative hypertrophy of the medial head of the gastrocnemius 
muscle (Fig. 1D, lower panel, arrows), the soleus muscle, and the flexor hallucis longus muscle (Supplementary 
Material 2).
Moreover, in all the patients edema-like changes of the affected muscles (being a hallmark of ongoing disease 
activity in the muscles24), manifesting as increased signal in STIR (Short Tau Inversion Recovery) sequences,were 
seen (Supplementary Material 2).
Morphological analysis of biopsied muscles. Hematoxylin/eosin (HE) staining of muscle transverse 
sections of the patients’ biopsies revealed variable primary myopathic changes (Fig. 2 and Table 2). The changes 
were either mild as in the case of patient 2 or very severe as in the case of patient 1 (Fig. 2). Variability in the fiber 
size was observed in all the biopsied muscles and centrally positioned myonuclei were visible as well. Also, vari-
able changes in stainings for the alkaline ATPase and NADH activities were visible, indicating a different state of 
muscle degeneration of biopsied muscle. The summary of the described morphological changes is presented in 
Table 2.
Genetic analyses. WES identified on average 66,873 genetic variants per patient, of which 45,156 off-target 
(defined as intergenic or intronic, but not affecting splice sites) were removed from further consideration. In 
total variants in 1,153 genes were further analyzed. In every filtering/prioritization approach mutations in ANO5 
were ranked first on the results lists. The identified changes are rare, with a minor allele frequency below 0.1% 
(see Table 3). According to our ANO5 model that has been created for the purpose of this study, Tyr23, Asn64, 
p.Asp81 and Lys132 residues are situated within the cytoplasmic domains, Arg758 is facing the extracellular 
matrix, while the other residues (Trp401, Ser555, Tyr 671 and His841) are located in the central part of the mol-
ecule, mostly within the transmembrane α-helices (Figs 3 and 4). The variants were deemed pathogenic by at 
least one prediction program: Mutation Taster, Polyphen2 PROVEAN or SIFT, and were absent in our in-house 
database of 110 Polish exomes/genomes (see Table 3)25–28. In addition, His841Asp was predicted by dbscSNV as 
potentially altering splicing with both its adaptive boosting (ada_score) and random forest (rf_score) scores larger 
than 0.629. All these variants were individually assessed by a board of geneticists and clinicians according to the 
Patient Gender Family history
Age at onset/
biopsy in yrs First symptoms Clinical phenotype
Asymmetry/
location
CK 
range EMG + ENG
Age of last 
examination
1 M
Reportedly 
older brother 
had similar 
symptoms
Third decade/54
Gait 
disturbances, 
myalgia
Progressive muscle 
weakness with limb-
girdle distribution, 
most pronounced in 
posterior thigh muscles. 
Two episodes of cardiac 
insufficiency. Alcoholism 
in anamnesi
+/upper limbs 19x
Myogenic in proximal 
muscles, mixed 
in distal muscles. 
ENG-motor-sensory, 
axonal-demyelinating 
neuropathy
Died in 2016 
COD unknown
2 M Sporadic 22/22
Myalgia, 
exercise 
intolerance
Mild generalized 
hypertrophy, right 
scapular winging
+/calves 20–50x Mild myopathic changes, ENG normal 30
3 M Sporadic Third decade/36
Episodic 
myalgia and 
muscle cramps
Mild generalized muscle 
hypertrophy
+/calves and 
qadriceps 10–15x Normal 36
4 F Sporadic 38/38 Myalgia, gait disturbances
Slowly progressing mild 
weakness of upper and 
lower extremities
+/calves 3–8x Normal 41
5 F Sporadic 25/42 Weakness of the right lower limb
Slowly progressing 
weakness of lower 
and upper limbs-with 
waddling gait and calf 
muscles involvement
+/lower and 
upper limbs 9–20x
Myopathic in upper 
limbs, normal in VL 42
Table 1. Summary of patients’ clinical history. M, male, F, female, CK-creatine kinase, EMG-electromyography, 
ENG-electroneurography, COD- cause of death, VL-vastus lateralis.
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Figure 1. Magnetic Resonance Imaging (MRI). (A–D) Selected axial T1W images of muscles of patients 2–5. 
(A) Images of patient 2 thigh muscles - arrow points to fatty atrophy in right adductor longus muscle; asterisk 
marks biopsied left vastus lateralis muscle with a mild fatty degeneration (arrowhead). (B) Images of patient 3 
thigh muscles - arrow points to severe fatty atrophy in left adductor longus muscle; asterisk marks biopsied left 
vastus lateralis muscle. (C) Images of patient 4 muscles; upper panel - thigh muscles with biopsied left vastus 
lateralis muscle (asterisk); lower panel - arrows point to fatty atrophy in medial head gastrocnemius muscles. 
(D) Images of patient 5 muscles; upper panel - arrows point to fatty infiltrations in biceps brachii muscles, 
asterisk marks biopsied left biceps brachii muscle; lower panel - arrows point to severe bilateral fatty infiltration 
of the soleus and gastrocnemius muscles.
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guidelines of the American College of Medical Genetics and Genomics30. Also, several other accompanying muta-
tions in muscle genes have been identified. Unfortunately, segregation analysis could not be performed because 
of the unavailability of the DNA samples of the relatives. A detailed list of accompanying mutations for patients 1 
and 2 was presented in23, and for patients 3–5 is presented in Supplementary Material 3.
Molecular modeling. To predict the impact of identified mutations on the ANO5 structure and hence func-
tion, we created a de novo model of ANO5 and its dimer (see Materials and Methods section, and Fig. 4A,B). The 
models were subjected to molecular dynamics (MD) analyses that enabled visualization of both local and global 
effects of the identified mutations (Figs 3–5 and Supplementary Materials 4–7, and Table 4). The analyses were not 
performed for the nonsense mutations (p.Trp401Ter, p. Tyr23Ter) and a frameshift p.Asn64LysfsTer15 mutation, 
which de facto also introduced the stop codon.
Local mutation effects. Local effects of the identified mutations were analyzed by investigating the conforma-
tional rearrangements around the site of mutation (Fig. 3A–L). To this end, hydrogen bonding and hydrophobic 
contacts throughout the simulations were accounted. The results indicate that two mutations to cysteine, p.Tyr-
671Cys and p.Arg758Cys, thoroughly change a role of mutated residues in local interaction networks (Fig. 3G–J). 
In particular, p.Arg758Cys mutation, the site of which is located on a distant-from-the-interface surface loop 
753–822 (Figs 3I,J and 4B), caused the relatively short residue of Cys758 to lose almost entirely several hydro-
gen contacts with residues from the same loop (especially with Glu816, His821 and Asn822) and with Met823 
from a short helical segment 823–825. All of them were maintained by the long and strongly polar residue of 
arginine 758. Instead, Cys758 maintains a strong H-bond contact with Gln824 and a weak contact with Asn817. 
In addition, positions of Arg758 and Cys758 are stabilized on a similar level (although more persistently in the 
case of Arg758) due to hydrophobic contacts with Ile756 and Met823 (to Arg 758) and Val760 and Tyr761 (to 
Cys758) (Fig. 3I,J, Supplementary Material 4: Tables 8 and 9). Furthermore, there is a weakened stabilization of 
the mutated residue of Cys671 compared to the wild-type residue of Tyr671 (Fig. 3G,H). This site is located in 
α-helix 669–684 in the core of each subunit ~15 Å from the dimerization interface (Figs 3G and 4A,B). In the 
Figure 2. Analysis of morphology of the patients’ muscles. The panels present routine stainings with 
hematoxylin/eosin (bars 50 μm) as well as for the alkaline ATPase and NADH activities (bars 150 μm).
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wild-type structure, Tyr671 maintains medium persistent H-bonds with Glu675 from the same α-helix and with 
Gly668 from a short loop 664–668 as well as strong H-bond with Arg234 from a surrounding loop 222–237 
(Fig. 3G). In the p.Tyr671Cys mutant structure, Cys671 loses the H-bonds with Glu675 and Arg234, and only pre-
serves the H-bond with Gly668 (Fig. 3H). In addition, Tyr671 interacts hydrophobically with Met560 from a long 
Age at 
biopsy
Biopsied 
muscle Atrophy
Hyper­
trophy Splitting Necrosis
Phago­
cytosis
Regen­
eration
Internal 
nuclei
Endomysial 
infiltrations
Endomysial 
connective 
tissue
Endomysial 
fatty tissue General conclusion
Patient 1 54 BB +++ − − + − + + + +++ +++ Advanced dystrophic changes
Patient 2 22 VL + + + − − + ++ − + −
Discrete myopathic 
changes suggesting 
DM2
Patient 3 36 VL + + + − − + ++ − − −
Moderate 
uncharacteristic 
myopathic changes
Patient 4 38 VL ++ + + − − − + + + +
Moderate 
uncharacteristic 
myopathic changes.
Patient 5 42 BB ++ ++ + ++ ++ ++ + + + +
Advanced dystrophic 
changes suggesting 
dysferlinopathy
Table 2. Morphological analysis of muscle biopsy. BB, biceps brachii; VL, vastus lateralis; −, not observed; +, 
minimal; ++, moderate; +++, advanced; DM2, myotonic dystrophy type 2.
cDNA 
ENST00000324559,8 
NM_213599.2
Protein 
ENSP00000315371.8 
NP_998764.1 Type
Effect on protein 
PolyPhen2/SIFT
Location 
GRCh38
Frequency 
in Exac 
database
ACMG evidence 
of pathogenicity
Accompanied 
heterozygous 
mutations with 
a predicted 
damaging effect*
Patient 1
c.242A>G p.Asp81Gly missense probably damaging/ deleterious 11:22221158 2.25e-04
PS4, PM3, PP3, 
PP4, PP5
BAG3, c.380C>T
p.Ser185Leu; 
7.63e-5
FNLC, c.2846A>G
p.Asp949Gly; 
3.89e-04
c.1203G>A p.Trp401Ter nonsense stop gained /deleterious 11:22255393 0 PVS1, PM2, PM3, PP3, PP4
Patient 2
c.242A>G p.Asp81Gly missense probably damaging/ deleterious 11:22221158 2.25e-04
PS4, PM3, PP3, 
PP4, PP5 NEB c.9055G>A
p.Ala3019Thr 
6.62e-05c.2272C>T p.Arg758Cys missense probably damaging/ deleterious 11:22274605 3.30e-05
PS4, PM3, PP3, 
PP4, PP5
Patient 3
c.69C>A p.Tyr23Ter nonsense stop gained /deleterious 11:22203832 9.84e-06 PVS1, PM2, PM3, PP4 RYR1, 2654G>A
p.Arg885His; 
1.77e-04c.1664G>T p.Ser555Ile missense possibly damaging/ deleterious 11:22262162 7.42e-05 PM3, PP3, PP4
Patient 4
c.395A>T p.Lys132Met missense probably damaging/ deleterious 11:22227333 0
PM2, PM3, PP3, 
PP4
COL12A1, 
c.6752G>A
p.Arg2251His; 
3.73e-04
FNLC, c.3721C>T 
p.Arg1241Cys; 
1.08e-02
LAMA2, 
c.2462C>T
p.Thr821Met; 
2.03e-03
c.2521C>G p.His841Asp missense / splice site
probably damaging/ 
deleterious 11:22279544 1.67e-05
PM2, PM3, PP3, 
PP5, PP4
Patient 5
c.191dupA p.Asn64LysfsTer15
frameshift, 
essential 
splice
frameshift/ deleterious 11:22221107 1.03e-03 PVS1, PM3, PP4, PP5
AGRN, 
c.3353C>A
p.Thr1118Lys; 
2.15e-03
ITGA7, 
c.3371G>A
p.Arg1124Gln; 
4.01e-04
ITGA7, 
c.2656G>A
p.Glu886Lys; 
4.01e-03
LAMB2, 
c.2891G>A
p.Arg964Gln; 
2.48e-05
c.2012A>G p.Tyr671Cys missense probably damaging/ deleterious 11:22270425 8.24e-06
PM2, PM3, PP3, 
PP4
Table 3. Heterozygous mutations identified in ANO5 in Polish patients. *With at least one prediction program: 
Mutation Taster, Polyphen2, PROVEAN or SIFT; in italic, mutations not registered in the gnomAD database.
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Figure 3. Local effects of mutations on ANO5 structure. Most occupied hydrogen bonds and hydrophobic 
interactions (green and light purple dashed lines, respectively) for the wild-type (left panels) and mutant sites 
(right panels) at positions: p.Asp81Gly (A,B), p.Lys132Met (C,D), p.Ser555Ile (E,F), p.Tyr671Cys (G,H), 
p.Arg758Cys (I,J) and p.His841Asp (K,L). The mutated residues at positions 81, 132, 555, 671, 758 and 841 are 
shown in magenta, while all residues interacting with them are shown in blue. All remaining parts of the protein 
are shown as line ribbons and colored according to secondary structure assignment (α-helices in brown and 
β structures in green). Hydrogen bonds occurring in the trajectory but not in the average structures lack the 
dashed lines. Their appearance in the figure consists solely in the presence of both residue 81, 132, 555, 671, 758 
or 841 (magenta) and its interacting partner (blue).
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α-helix 549–568 (strong contact) and Lys233 from the loop 222–237 (periodic contact), compared with Cys671 
loosing entirely the former and almost entirely the latter contacts (Fig. 3G,H; Supplementary material 4: Tables 6 
and 7). Moreover, the replacement of tyrosine with cysteine within the 669–684 α-helix perturbs the symmetry of 
the N-terminal end of this α-helix (residues 669–674), resulting in the disruption of periodic hydrogen bonding 
and subsequently weakened, less persistent local α-helical structure (see secondary structure assignment for this 
α-helix in the wild type and Tyr671Cys mutant in Supplementary Material 5).
Figure 4. Global effects of mutations on ANO5 structure. (A,B) Models of ANO5 monomer and dimer, 
respectively. Residues undergoing missense and nonsense mutations are shown as yellow and purple sticks, 
respectively. (A) Flat ribbon representation of the ANO5 monomer. For space limitation, the residues are 
presented in the single-letter code. C- and N-termini are shown as olive CPK spheres, respectively. The α-helices 
A1 (residues 609–639) and A2 (residues 692–715) are shown in red. Cytoplasmic and extracellular domains 
are facing the top and bottom of the figure, respectively. (B) Model of ANO5 dimer in the tube representation 
with location of the mutated residues. Subunits A and B are colored in blue and orange, respectively, and 
residues forming dimerization interface are shown as spheres and color-coded as above. For space limitation, 
the residues are presented in the single-letter code. (C–I) Effects of mutations on the dimer interface. Left 
panels, close view of the central α-helices at the dimerization interface of the wild-type (C) and mutants (D–I) 
ANO5 structures. (D) p.Asp81Gly, (E) p.Lys132Met, (F) p.Ser555Ile, (G) p.Tyr671Cys, (H) p.Arg758C, (I) 
p.His841Asp. Helix A1, blue; helix A2, cyan, helix B1, red; and helix B2, orange. Subunits A and B are colored in 
green and straw, respectively. Hydrophobic interactions and hydrogen bonds between helices from subunits A 
and B are shown as light violet and green dashed lines, respectively. Right panels, concerted motions associated 
with the first eigenvectors (PC1) in PCA-2 for the four central α-helices: A1 (blue), A2 (cyan), B1 (red) and B2 
(orange). The actual frames represent the average structures from the first mode of motion. Residues forming 
the helices are shown as C-α van der Waals spheres. Motions are represented by green arrows indicating the 
direction of motion and its amplitude.
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Figure 5. Eigenvector analysis. Plot of eigenvalues corresponding to the eigenvector index for the first 10 
modes of motion in the PCA-1 (in (A)) or PCA-2 (in (B)) analyses carried out for the wild-type and mutant 
ANO5 dimer structures. (C), time development of projections of 2 features (distance-dependent functions) 
obtained from PCA-3 analysis of the central α-helices at the dimerization interface in the wild-type and mutant 
ANO5 structures. Color legend in (C) ANO5, black; p.Asp81Gly, red; p.Lys132Met, green; p.Ser555Ile, blue; 
p.Tyr671Cys, cyan; p.Arg758Cys, magenta; and p.His841Asp, orange.
Model
Chain A Chain B Interface A­B
N(at) N(res)
Surface 
[Ẳ2] N(at) N(res)
Surface 
[Ẳ2]
Surface 
[Ẳ2]
ΔG 
[kcal/
mol]
ΔG 
P­value
ANO5 279 70 42474 307 85 41873 2520.7 −39.7 0.142
p.Asp81Gly 358 94 48767 345 88 48092 3033.2 −36.2 0.661
p.Lys132Met 376 97 47313 381 97 48815 3314.8 −47.0 0.375
p.Ser555Ile 456 121 47717 433 110 49308 3887.3 −46.8 0.713
p.Tyr671Cys 375 105 40483 358 102 39668 3226.0 −48.9 0.202
p.Arg758Cys 360 90 46726 348 91 48777 2977.8 −27.8 0.906
p.His841Asp 320 90 47315 323 92 47046 2844.7 −42.6 0.243
Table 4. Selected parameters from PISA evaluation of the dimerization interfaces in ANO5 and its mutants. 
PISA, protein interfaces, surfaces and assemblies service at the European Bioinformatics Institute (http://www.
ebi.ac.uk/pdbe/prot_int/pistart.html); N(at) and N(res) indicate the number of interfacing atoms and residues, 
respectively. ΔG and ΔG P-value indicate the solvation free energy gain and the P-value of the solvation free 
energy gain, respectively.
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However a different picture can be seen in the case of the p.His841Asp mutation, which is located in the sur-
face α-helix 834–849, nearby the site of the p.Arg758Cys mutation (Fig. 4A,B). In the mutant structure, Asp841 is 
coordinated with hydrogen bonds more persistently than His841 in the wild-type structure(Fig. 3K,L). However, 
the imidazole side chain of His841 is engaged in several hydrophobic contacts, including with Phe844 and Leu845 
from the same α-helix and with Arg364 from a surrounding short surface loop 232–234 (Fig. 3K). Such a stabili-
zation cannot be reached upon mutation to a polar residue of aspartate and hence the p.His841Asp mutant loses 
all the mentioned hydrophobic contacts, rendering histidine (His841 in the wild-type structure) as an overall 
better stabilized residue (Fig. 3K,L, Supplementary Material 4: Tables 10 and 11).
The other two mutants, p.Asp81Gly (Fig. 3A,B) and p.Ser555Ile (Fig. 3E,F), show less distinct rearrangements, 
accounted for as differences in local interaction networks with respect to the wild-type structure. Asp81, located 
at the dimerization interface in the loop 71–83 (Fig. 4B), is strongly saturated with H-bonds to Arg78; these 
interactions appear to be crucial in stabilizing the position of Asp81 in the wild-type structure. Nevertheless, 
other H-bond contacts of Asp81 are very limited and even less persistent than the hydrogen bonds maintained 
in the mutant structure by Gly81 (Fig. 3A,B, Supplementary Material 4: Table 1). Ser555, located in the core 
α-helix 549–568 (Fig. 4A), maintains a very strong H-bond with neighboring Glu544 and two much less persis-
tent H-bonds with Glu551 and Lys559 (Fig. 3E), compared to the lack of the Glu544 contact and more persistent 
contacts with Glu551 and Lys559, maintained in the p.Ser555Ile mutant structure by Ile555 (Fig. 3F). In addition, 
the aliphatic side chain of Ile555 is mildly engaged in hydrophobic interaction with the pyrrolidine side chain of 
Pro546, whereas Ser555 lacks the hydrophobic stabilization at all (Fig. 3E,F, Supplementary Material 4: Tables 4 
and 5).
Contrary to the other analyzed mutations, the local effect of the p.Lys132Met mutation, located close to the 
dimerization interface at the C-terminal end of the β-strand 126–132 (Fig. 4B), is neither unfavorable nor at 
most neutral as it seems to stabilize the local protein structure. This can be observed in the larger occupations of 
both hydrogen bonds and especially hydrophobic interactions maintained by Met132 in comparison to Lys132 
(Fig. 3C,D). Met132 forms, both as a donor and acceptor, persistent H-bonds with Leu115 from a surround-
ing loop 106–115. Moreover, there is a strong hydrophobic contact between side chains of Met132 and Leu115 
(Fig. 3C,D). Conversely, Leu132 interacts with Leu115 less strongly, forming with it a less persistent H-bond 
(only as a donor) and maintaining a much less persistent hydrophobic contact (Fig. 3C). Besides, unlike Leu132, 
Met132 maintains yet another stabilizing interaction, i.e. a very strong hydrophobic contact with Ala135 from a 
surrounding short loop 133–136 (Fig. 3C,D, Supplementary Material 4: Tables 2 and 3).
Global mutation effects. Stability of the dimerization interface in view of the effects on central α-helices: 
Parameters from the PDBePISA evaluation of dimerization interfaces in the average structures from the stable 
parts of trajectories of the wild-type ANO5 and its six single mutants are shown in Table 4. There is a diversity of 
the calculated interface surfaces and the estimated solvation free energy gains upon formation of the interface. 
The ΔG P-values, indicating the P-value of the observed solvation free energy gain, are either below or above 0.5. 
This allows the distinction between hydrophobic, interaction-specific interfaces, observed for wild type ANO5 
and its mutants: p.Tyr671Cys, p.His841Asp and p.Lys132Met (ΔG P-values below 0.5), from interfaces that are 
more “random”, i.e. less hydrophobic than they optimally could be, observed for ANO5 mutants p.Asp81Gly, 
p.Ser555Ile and p.Arg758Cys (ΔG P-values significantly above 0.5). Therefore, the ΔG P-value is an impor-
tant overall indication of the differences in hydrophobic character of the dimerization interfaces in the modeled 
sample.
The dimerization interface in the ANO5 structure and its mutants is composed of four central α-helices. Each 
subunit contributes two α-helices [609–639 (A1) and 692–715 (A2) in subunit A and, symmetrically, 1523–1552 
(B1) and 1605–1628 (B2) in subunit B] together with surrounding loops and a few patches from other helices 
(see Fig. 4A,B). As expected, based on their buried location in the protein, these central α-helices are of mostly 
hydrophobic character. The conservation of this hydrophobic core during MD simulations can be evaluated by 
counting up the hydrophobic contacts present in the trajectories and in the average structures between hydro-
phobic residues from each of the central α-helices (Supplementary Material 4: Table 12, and Supplementary 
Material 5). These results are in accordance with the PDBePISA ΔG P-values. The highest number of contacts 
between subunits (20) was predicted for the wild type protein with 12 contacts between subunits A and B of the 
dimer (Supplementary Material 4: Table 12; Fig. 4C, left panel). The low and thus disadvantageous number of con-
tacts is calculated for the p.Asp81Gly and p.Arg758Cys mutants with five and four contacts, respectively, and only 
with three contacts between residues in subunits A and B of both mutants (Supplementary Material 4: Table 12 
and Fig. 4D,H, left panels). The higher number of contacts, 15, is predicted for the p.Ser555Ile mutant with nine 
intersubunit contacts (Supplementary Material 4: Table 12 and Fig. 4F, left panel). Similar values were calculated 
for other mutants with 17(6) for p.Lys132Met, 14(9) for p.His841Asp and 14(7) for p.Tyr671Cys (numbers in 
parenthesis reflect the intersubunit contacts) (Supplementary Material 4: Table 12; Fig. 4E,H,I, left panels). The 
percentage of trajectory occupancies of all hydrophobic contacts between residues of the four central α-helices 
of the analyzed structures are listed in Supplementary Material 4: Table 12. Moreover, only the wild-type protein 
shows the contacts from the A1 α-helix distributed equally to the B1 and B2 α-helices, whereas in all the mutant 
structures the contacts from the A1 α-helix reach exclusively the B1 α-helix, putting the B2 α-helix totally aside. 
It means the larger segment of interface stabilization, embracing the A1, B1 and B2 central α-helices, to be pres-
ent only in the wild-type structure, in contrast to all mutant structures contributing to the stabilization pool only 
the A1-B1 α-helices’ interactions. Furthermore, in the trajectory of the wild-type structure there are two strong 
H-bonds linking the A1 α-helix with the B1 α-helices (Tyr632-Ile1540, occupied at 71.9% of the analyzed tra-
jectory) and B2 (Ile627-Trp1623, occupied at 57.4%), which seem to consolidate even further the dimerization 
interface. On the contrary, in their own trajectories, the mutant structures lack similarly persistent H-bonds at the 
central helices. Besides, all H-bonds occupied above 10% of the mutants’ trajectories (between Asn626-Asn1550, 
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occupied at 45.2% in the p.Asp81Gly mutant; between Trp638-Thr1532, occupied at 31.7% in the p. His841Asp 
mutant; and between Trp638-Thr1532, occupied 27.5% in p.Lys132Met) are formed solely between the A1 and 
B1 α-helices. Unlike in the wild-type protein, the B2 α-helix is not engaged in all those H-bonds (Fig. 4C–I and 
Supplementary Material 4: Table 13).
The secondary structure content throughout the simulations (see Supplementary Material 5) shows that the 
p.Asp81Gly and, to a lesser extent, p.His841Asp mutations perturb the central helices. This results in their accu-
mulated average α-helical assignments of 70.4% and 74.1%, respectively, compared to 78.7% for the wild-type 
structure. The values for the p.Tyr671Cys, p.Ser555Ile and p.Lys132Met mutants were similar to that of the wild 
type and were 76.7%, 77.8% and 77.9%, respectively. Interestingly, the p.Arg758Cys mutation even strength-
ened the α-helical assignment of the four central helices, bringing it to an accumulated average of 85.2% 
(Supplementary Material 5).
Essential Dynamics: Essential dynamics was performed to enable identification of concerted motions that are 
often fundamental for protein functions31–33. In the present work, three Principal Component Analyses (PCA) 
were performed: first based on the decomposition of the global conformational space (PCA-1), second on the 
conformational space explored by four central helices (PCA-2), and the third on the distances between the central 
helices (PCA-3) (Figs 4C–I, right panels, and 5, as well as Supplementary Materials 6 and 7).
The eigenvalues against the corresponding eigenvector index for the first 10 modes of motion are plotted 
for the PCA-1 and PCA-2 analyses (Fig. 5A,B, respectively). It demonstrates that only few modes of motion are 
required to explain the majority of variance in the motions. Indeed, the first eigenvectors (PC1) alone explain 
29.5–37.6% or 13.4–40.6% of the total variance in the motions observed in PCA-1 or PCA-2, respectively. 
Together with the second (PC2) as well as the second (PC2) and third eigenvector (PC3) the explanatory rate 
increases to 41.0–50.3% and 30.5–62.6%, for PCA-1 and PCA-2, respectively. The correlation coefficients (r2), 
computed from the time evolution of trajectories projected on the first eigenvector and plotted for each pair com-
posed of the wild-type protein and mutant, show the motions associated with PC1 being either analogous (ANO5 
versus p.Ser555Ile and ANO5 versus p.His841Asp) or strongly analogous between the wild-type protein and the 
mutant systems in PCA-1. On the other hand, r2 are very poorly correlated between ANO5 and its mutants in 
PCA-2 (Supplementary Materials 6 and 7). It demonstrates that while the motions are similar on the global scale, 
the local motions pertaining to the central helices are not similar at all, i.e. they do not repeat the same pattern.
Investigating further the eigenvalues against eigenvector index plots in Fig. 5B, a very shallow PCA-2 profile 
can be observed for ANO5, indicating the concerted motions associated with different eigenvectors in ANO5 to 
be of similar explanatory relevance. In addition, the PC1 motions in mutant structures have slightly (p.Ser555Ile) 
through moderately to largely (p.His841Asp and p.Lys132Met) higher amplitudes compared to the PC1 motion 
in ANO5. It indicates that the central helices in mutated structures undergo larger PC1 motions compared to the 
wild-type protein (see Fig. 4C–I, right panels, Supplementary Materials 6 and 7). It points to supposedly desta-
bilizing effects of the mutations, as can be concluded also from the comparison of the plots depicting the PCA-2 
motions associated with PC1 (Fig. 5 and Supplementary Material 7). The consolidated position and moderate 
motions of the central helices in the average structure from the PC1 motion mode of ANO5, compared with 
less ordered position and more “random” motions of those helices in all mutant structures are noticed there. 
Moreover, the “subtle” PCA-2 motions associated with PC2 and PC3 in ANO5 (see Supplementary Materials 6 
and 7), worth of considering due to similar explanatory relevance of the first three modes of motion of ANO5, do 
not overrule the picture emerged from the comparison of the motions associated with PC1.
An incisive dependence pattern of the amplitudes (eigenvalues) associated with eigenvectors, observed in 
PCA-2, does not occur in PCA-1, where the amplitudes of the PC1 motions are less mutually different and the 
eigenvalue associated with PC1 in ANO5 is not the smallest one in the series (Fig. 5A,B, and Supplementary 
Materials 6 and 7). Nevertheless, the concerted motions associated with PC1 in ANO5 appear to be the most 
ordered in the series, with few surface segments and the central loop 1409–1424 from subunit B moving while 
the rest of the structure remaining virtually still (Supplementary Material 7). Overall, all mutants appear to be 
more “restless”, with concerted motions involving large parts of their structures, which is especially evident in 
the p.Tyr671Cys, p.Lys132Met, p.R758C and p.His841Asp mutants (see Supplementary Material 7). But given 
that, the results of PCA-1 do not seem to provide a clear message on the differences potentially destabilizing the 
mutant structures compared to the wild-type protein.
The PCA-3 analysis can be considered as complementary to PCA-2. The two obtained features were able to 
explain ~90% of variance in the dataset. Results plotted on Fig. 5C show the time development of projections 
of the functions characterizing distances between the central α-helices along PC1 vs PC2. Figure 5C presents a 
separate localization and concentrated appearance of the wild-type protein (black) and different localizations and 
more dispersed appearances of all mutant structures, though less so of the p.Ser555Ile mutant (blue). It suggests 
(and possibly confirms) the stable behavior of the central α-helices in the wild-type structure in contrast to less 
stable/more perturbed behaviors of those helices and, in turn, of the dimerization interface, in mutant structures. 
In particular, the p.Asp81Gly and p.His841Lys mutants (red and orange, respectively) appear to be significantly 
different from all other mutants and from the wild-type protein, while mutants p.Lys132Met (green), p.Arg-
758Cys (magenta), p.Tyr671Cys (cyan) and p.Ser555Ile (blue) also differ from the wild-type protein but exhibit 
mutual similarity when described with two PCA-derived features. p.Asp81Gly and p.His841Asp mutants are the 
ones in the series with weakened α-helical secondary structure assignments within the central α-helices. Besides, 
A1 and A2 α-helices in the p.His841Asp mutant are found wandering quite a lot during the first mode of motion 
(see Supplementary Material 7), the one explaining as much as 46% of the total motion variance in PCA-2. This 
wandering perturbs their between-helices-distances, which appears to be reflected in a very strongly dispersed 
appearance of His841Asp on the plot, with A1 and A2 helices either in contraction or separated (approximately 
two parts of the His841Asp appearance on the plot in Fig. 5C).
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Discussion
We presented herein clinical and diagnostic data of five Polish patients with ANO5 heterozygous mutations and 
clinical diagnosis of LGMD2L. Analyses of both clinical phenotypes and muscle morphology (based on histo-
chemistry and MRI) revealed a high degree of variability. The MRI imaging also showed a high degree of varia-
bility of changes in different muscles in the same patient, making the LGMD2L picture even more complicated.
Genetic analysis identified nine mutations, among them three: p.Tyr23Ter, p.Lys132Met and p.Trp401Ter were 
not yet characterized and the latter two not even registered in the gnomAD database. The other six mutations: 
p.Asn64LysfsTer15, p.Asp81Gly, p.Ser555I, p.Tyr671C, p.Arg758C and p.His841Asp have been already described 
in the European population9,21,22 as damaging, implying their contribution to the observed pathology.
The two newly characterized nonsense mutations introduce a premature stop codon and most probably lead 
to degradation of a truncated protein through proteasomal pathways23,31,32. The lack of the full length ANO5 pro-
tein was recently shown for the homozygous p.Asn64LysfsTer15 (c.191dupA) mutation that in fact introduce a 
premature stop codon (see34). In many genes (e.g. DMD, RYR1) the presence of frameshift or nonsense mutations 
is often associated with a severe disease course35.
To characterize the effects of missense mutations on the ANO5 structure, and possibly function, we employed 
molecular dynamics analyses. For this purpose, models of the monomer and dimer structure were created. The 
models were generally analogous to the models presented by Andreeva et al.17. However, the number of trans-
membrane helices depicted in our model surpasses the number declared by those authors. Unfortunately, more 
detailed comparison of both models is impossible due to the lack of access to the aforementioned models.
Analysis of the local effects indicated that the most visible changes were observed for p.Tyr671C and 
p.Arg758C mutants, both associated with the introduction of a cysteine residue, much smaller than the original 
arginine and tyrosine residues but also prone to form new interactions. On the other hand, p.Asp81Gly (intro-
ducing a small glycine residue) and p.Ser555Ile (introducing a hydrophobic isoleucine residue) mutations have 
much less impact on local conformational rearrangements. Contrary to that, the novel p.Lys132Met (introducing 
a similar in molecular mass but non-polar and sulphur containing methionine residue) mutation seems to rather 
stabilize (stiffen) the local protein structure. Interestingly, Asp81 and Tyr671 as well as Lys132 residues are situ-
ated either at the dimerization interface (Asp81) or in its vicinity (Tyr671 and Lys132). Thus the local effects of 
the mutations on the protein structure are variable and do not depend on the localization of the mutated residues 
within the molecule. However, they could influence the protein dimerization and so we examined the effects of 
the mutations on the dimerization interface.
We predict that all the analyzed mutations affect dimer formation. In particular, the Asp81Gly and Arg758Cys 
mutations appear to have a strong detrimental effect on the stability of the dimerization interface as shown by 
the high ΔG P-values, low overall numbers and lack of balanced pattern of hydrophobic contacts, lower SSC (for 
p.Asp81Gly) as well as lack of (for p.Arg758Cys) or weakened (for p.Asp81Gly) hydrogen bonds. More elaborate 
although ultimately disadvantageous seem to be the effects of the p.Ser555Ile (the high ΔG P-value, lack of bal-
anced hydrophobic interactions pattern and lack of strong hydrogen bonds) and p.His841Asp (lower SSC, lack 
of balanced hydrophobic interactions pattern, weaker hydrogen bonds compared with the wild-type system) 
mutations. The other two mutations, p.Lys132Met and p.Tyr671Cys, exhibit both a less balanced hydrophobic 
interactions pattern, and the lack of (for p.Tyr671Cys) or weakened (for p.Lys132Met) hydrogen bonds, with both 
these features expectedly lowering the stability of the dimerization interface.
Moreover, essential dynamics analysis revealed that all analyzed mutations affect the concerted motions of 
the ANO5 dimer and have supposedly destabilizing effects as central α-helices of mutant structures undergo 
larger motions with respect to the wild type protein. All the mutants appear to be more motile (restless) with 
larger parts of the protein engaged in the concerted motions. In particular, this was most evident in p.Lys132Met, 
p.Tyr671C, p.Arg758C and in particular in p.His841Asp. Thus the results of essential dynamics highlight the dif-
ferences between the wild-type protein and the mutant structures on the ground of less stable central α-helices at 
the dimerization interface, that in mutant proteins undergo larger and seemingly more random motions. These 
dynamic structural differences could therefore result in damaging/deleterious effects on the protein function.
The question arises whether and how particular mutations affect the protein conformation and influence the 
patients’ phenotype. Patient 1, with most severe dystrophic changes, bore a p.Trp401Ter truncation mutation 
and p.Asp81Gly missense mutation. The nonsense mutation introduces premature stop codon located in the 
proximity of the final exon-junction thus suggesting elimination of the mRNA through the nonsense mediated 
decay. The latter mutation was also found in patient 2 where it co-existed with a missense p.Arg758Cys mutation, 
which also had negative impact on the dimerization interface. Despite carrying mutations that negatively affect 
dimerization, patient 2 presented mild myopathic changes (in clinical and MRI examinations) but with early 
disease onset. Interestingly, the same pair of mutations has been already identified in a Finnish male patient with 
the similar disease onset and clinical phenotype20. Of note, the p.Arg758Cys mutation is considered as a founder 
mutation in the Finnish population36. Patient 3, bearing the novel p.Tyr23Ter truncation and known missense 
p.Ser555Ile mutation (with disadvantageous effect on dimer formation), also presented mild muscle involvement 
but with disease onset in third decade of life. Patient 4 bears a novel p.Lys132Met mutation accompanied by a 
known p.His841Asp mutation that was first described in a British patient as homozygous and was predicted to 
be pathogenic22. Our analyses showed that both mutations affect the dimerization interface with p.His841Asp 
being more disadvantageous. This patient, with onset in his fourth decade presented a moderate phenotype. 
Patient 5 carries the most common p.Asn64LysfsTer15 mutation predicted to have deleterious effect on the pro-
tein function, and p.Tyr671Cys missense mutation, which as we showed strongly affected ANO5 conformation. 
This patient had disease onset in her third decade and presented advanced dystrophic changes.
The complexity to the picture is aided by the fact that numerous WES analyses have revealed mutation bur-
den in genes other than ANO5 that are also associated with LGMD phenotypes (for example9,20,23). These were 
depicted by prediction softwares either as benign/moderate or as deleterious/damaging and hence possibly 
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pathogenic. In our study, such accompanying variants were also found and differed among patients. Here, we 
will focus on those depicted by the prediction programs as potentially most pathogenic. Patient 1 had potentially 
phenotype-modifying missense variants found in BAG3, coding for BAG3 (BCL2 associated athanogene 3), a pro-
tein involved in the chaperone-assisted selective autophagy (CASA) pathway37 and in FLNC, coding for filamin 
C (FLNC), a protein involved in actin cytoskeleton organization. Interestingly, a missense FLNC variant was also 
identified in patient 4. Both FLNC variants, predicted as damaging, are located within Ig-like domains, mutations 
in which are also often associated with cardiomyopathy phenotypes38. It is noteworthy that patient 1 had cardiac 
failure but so far patient 4 has not reported any heart problems. The reported herein p.Ser185Ile BAG3 variant 
could affect chaperone function of the protein as even a mild impairment of the function could cause abnor-
malities in the sarcomere structure or dysfunctional protein folding quality control mechanisms39,40. Therefore 
it cannot be excluded that for patient 1 the observed muscle phenotype of ANO5 could be also exacerbated by 
BAG3 and FLNC variants. Patient 2 carries a variant in NEB, encoding a large protein regulating the length of thin 
filament in the contractile apparatus. NEB mutations are associated with a wide pattern of myopathic symptoms, 
and are often linked with nemaline myopathies41,42. We did not find nemaline rods in patient’s 2 biopsy indicating 
that the effect of this NEB mutation on the clinical phenotype seems to be rather minor. Patient 3 carries a known 
variant in RYR1, encoding skeletal muscle-type ryanodine receptor 1 (RYR1). Over 500 mutations have been 
mapped to RYRs and the majority of them are implicated in human diseases such as malignant hyperthermia 
as well as RYR1 myopathies, previously classified as central core disease (CCD) and multiminicore disease43,44. 
Identified RYR1 mutation, affecting a repeat within the cytoplasmic part of the protein, is reported in the ClinVar 
database with a note that there are conflicting interpretations of pathogenicity. Therefore we cannot conclude 
whether or not this variant could contribute to the observed phenotype of patient 3. Patient 4, besides the FLNC 
mutation mentioned above, carries mutations in COL12A1 and LAMA2, encoding isoforms of collagen 12 and 
extracellular matrix glycoprotein laminin A, respectively. Mutations within both genes could have deleterious 
effects on the skeletal muscle organization and function as they are associated with several myopathies, including 
LGMD, collagenoses and merosin deficient congenital muscular dystrophy45,46. The COL12A1 variant is listed 
in the ClinVar database as likely benign while the one in LAMA2 has contradictory predictions from benign to 
deleterious. We saw an increase in endomysial connective tissue infiltrations that could result from changes in 
collagen structure, however, they are much smaller than the ones observed in patient 1, who did not have variants 
in the gene encoding this collagen isoform. Moreover, it is also possible that minimal endomysial infiltrations 
could be associated with effects of mutation with LAMA2. However, mutations in both genes do not seem to 
greatly contribute to the observed phenotype. Interestingly, variants in several other genes involved in cell adhe-
sion, namely AGRN, encoding agrin, a protein crucial for the development of the neuromuscular junction (NMJ), 
ITGA7, encoding integrin subunit α7, and LAMB2, encoding laminin B2 isoform, were identified. Both AGRN 
and LAMB2 are associated with congenital myasthenic syndromes, associated with basal-lamina dysfunction47 
and ITGA7 mutations are associated with congenital muscular dystrophy48. Identified variants in these three 
genes could possibly affect sarcolemma and synaptic activity at the NMJ. Thus they could to some extent explain 
the observed phenotype, especially the changes in muscle morphology (as examined by MRI and histochemistry).
There is also another possibility that is beyond a scope of this study that changes evoked by ANO5 mutations 
(and/or by mutations in other muscle-related genes) could have effect on functions of unmodified genes. It could 
be speculated that impairment of ANO5 might affect other anoctamin isoforms and/or proteins involved in the 
same processes, in which ANO5 is engaged.
In conclusion, we have described five Polish LGMD2L patients with recessive mutations in ANO5 that accord-
ing to the criteria proposed by Antonarakis et al.49 and MacArthur et al.50 are highly likely to be disease-causing 
according to ACMG criteria (see Table 3). Our data, in frame with other recent results, indicate that recessive 
ANO5 mutations are a frequent cause of muscular dystrophy and are population-specific51–54. We showed that 
ANO5 mutations (possibly in concerto with other variants in numerous genes linked with myopathies) are asso-
ciated with the observed phenotypes. The severity of the clinical and morphological muscle impairment seems 
to be associated with the location of the mutation, and therefore its effect on ANO5 structure and function. 
However, there is not a direct correlation between the effects of mutations and clinical picture, probably due to 
mutation burden in other muscle-related genes. Finally, our data seem to support the ongoing hypothesis that 
LGMD and other dystrophies/myopathies could be in fact oligogenic disorders, with few mutated genes contrib-
uting unevenly to the development of the disease23,55.
Materials and Methods
Magnetic Resonance Imaging (MRI). The whole body MRI (WB MRI) was performed on 1.5 T scan-
ner (Siemens Avanto) with a multi-sequence imaging protocol. T1-weighted, T2-weighted and STIR (Short Tau 
Inversion Recovery) sequences were obtained in coronal planes with 5 mm slice thickness while T1-weighted 
and STIR sequences were obtained in axial planes with 8 mm slice thickness. Muscle bulk was assessed on 
T1-weighted images. Muscles were scored on axial T1-weighted sequences with the semi-quantitative56 visual 
scale modified by Fischer et al.57 to estimate the degree of muscle degeneration. STIR sequences were used to 
assess the presence and symmetry of edema-like changes.
Muscle biopsy. The open muscle biopsies of the probands biceps brachii or vastus lateralis were performed, 
and the muscle specimens were routinely processed for further analyses.
Light microscopy. Biopsied muscles were frozen in isopentane cooled in liquid nitrogen, cut on a cryomi-
crotome with a slice thickness of 8 µm and stained with the routine battery of histological and histochemical 
methods.
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Genetic analyses. DNA was extracted from peripheral blood of the proband using standard methods58. 
Whole exome sequencing (WES) was performed in two institutions: samples of patients 1 and 2 were sequenced 
commercially at Oxford Gene Technology (Oxfordshire, United Kingdom), and samples of patients 3, 4 and 5 
were sequenced at the Broad Institute’s Genomics Platform as part of the MYO-SEQ project coordinated by the 
John Walton Muscular Dystrophy Research Centre, Newcastle University.
Samples 1 and 2 were sequenced using SureSelect Human All Exon v4 enrichment kit and 100 bp paired-end 
sequencing on the Illumina HiSeq2000 platform. Fastq read files were generated from the sequencing platform 
via the Illumina software. The paired-end reads were aligned to the human genome build 37 (hg19) reference 
using Burrows-Wheeler Alignment (BWA) package59. Duplicate reads were removed with Picard and base quality 
Phred scores were recalibrated using Genome Analysis Toolkit (GATK) covariance recalibration60. Alignments 
were viewed with Integrative Genomics Viewer (IGV)61. Sequencing resulted in >80% of targets covered at least 
20x and a mean target coverage was 55x. Single Nucleotide Polymorphism (SNPs) and insertions/deletions 
(indels) were called using the GATK Unified Genotyper Annovar for initial variant annotation62 and further 
annotation, filtering and analysis performed on the Galaxy platform (on PL-Grid Infrastructure).
WES for samples 3, 4 and 5 was performed at the Broad Institute’s Genomics Platform, using Illumina exome 
capture and 76 bp paired-end reads on the Illumina platform. Fastq read files were generated from the sequencing 
platform via the Illumina software. The paired-end reads were aligned to the human genome build 37 (hg19) 
reference using Burrows-Wheeler Alignment (BWA) package59. Duplicate reads were removed with Picard and 
base quality Phred scores were recalibrated using Genome Analysis Toolkit (GATK) covariance recalibration 
(McKenna et al.60). Alignments were viewed with IGV. Sequencing resulted in >80% of targets covered at least 
20x and a mean target coverage was above 80x. SNPs and indels were called using the GATK HaplotypeCaller 
Default filters were applied to SNP and indel calls using the GATK Variant Quality Score Recalibration (VQSR) 
approach. Lastly, the variants were annotated using Variant Effect Predictor (VEP).
Filtering was based on the allele frequency in ExAC database (<3% for variants in genes already associated 
with LGMD, and <1% for variants in other genes), and predicted pathogenicity (predicted pathogenic by at least 
one out of Mutation Taster, PolyPhen2, and SIFT software). Prioritization was based on inheritance mode, on 
the predicted effect with truncating and elongating variants being evaluated more carefully, on predicted path-
ogenicity, and on known association with myopathic phenotypes reported in the Human Phenotype Ontology. 
Standardized phenotypic information was uploaded to PhenoTips63. Analyses were made with Exomiser2, 
PhenIX and Exome Walker with prioritization of variants based on possible association with Human Phenotype 
Ontology term “limb-girdle muscular dystrophy” and based on random-walk analysis of protein interaction net-
works64. ANO5 mutations and selected mutations in other genes (BAG3, FLNC, RYR1) were confirmed using 
direct, fluorescent sequencing (ABI 3130 Gemetic Analyzer, Applied Biosystems, USA).
Models of ANO5 and its mutants. A model of dimeric wild-type ANO5 protein was prepared in two 
steps: (i) the monomeric structure of ANO5 was generated using the intensive mode of Phyre2 algorithm65 based 
on the human ANO5 wild-type sequence (Q75V66 in the UnitProt Knowledgebase), and (ii) the monomer into 
dimer conversion was carried out using the M-ZDOCK server66. Modeling of both steps was performed with 
default settings implemented in the Phyre2 intensive mode and M-ZDOCK algorithms. 602 out of 913 residues 
in the ANO5 sequence (66%) were modeled by homology and rated by the Phyre2 algorithm as highly confident 
(above 90% of accuracy), while the rest of the structure was modeled ab initio due to the lack of respective homol-
ogy motifs.
The following single mutations were incorporated in the ANO5 dimer wild-type model in order to investigate 
their effect on the 3D structural level: Asp81Gly, Lys132Met, Ser555Ile, Tyr671Cys, Arg758Cys and His841Asp 
(Fig. 4A,B). Both the wild-type structure and all mutant structures were prepared to MD simulations according 
to the following protocol. Hydrogen atoms were added in tleap from AmberTools1667 according to standard 
protonation states of the amino acids. Resulting structures were immersed in truncated octahedral boxes of water 
molecules (TIP3P model68) extended up to 9 Å away from the protein surfaces. Monovalent sodium ions were 
placed in calculated positions to keep the neutrality of the simulation boxes.
Molecular dynamics (MD). The simulation setup was as follows. Initially, the models were subjected to 
mixed steepest descent and conjugate gradient energy minimizations carried out in two steps involving (i) only 
solvent molecules and (ii) the whole systems. Then, gradual heating to 300 K was performed in three 10 ps inter-
vals (0 → 100 K, 100 K → 200 K and 200 K → 300 K), followed by equilibrations at 300 K lasting for 10 ns. Finally, 
productive MD simulations in the NpT ensemble (conserved number of atoms (N), pressure (p) at 1 atm and tem-
perature (T) at 300 K) were performed and lasted for 130, 180 or 230 ns, depending on the simulation. Pressure 
and temperature were monitored by the isotropic position scaling and the weak-coupling algorithms, respectively, 
with both coupling times of 1 ps. Periodic boundary conditions were applied throughout simulations. Long-range 
electrostatic interactions were handled using the particle mesh Ewald method69 with a charge grid spacing of 
approx. 0.9 Å. All bonds involving hydrogen atoms were constrained using the SHAKE algorithm70 with a relative 
tolerance of 0.00001 Å, allowing a time step of 2 fs. Trajectories were saved at 2 ps intervals. All minimizations and 
MD simulations except the productive part were carried out with sander from AmberTools16 using the ff14sb 
force field71. Productive MD simulations were performed with pmemd using the same force field.
Trajectory analysis. Root mean square deviations (RMSD) of the backbone atoms from the collected tra-
jectories have been calculated with cpptraj72 from AmberTools16 to assess the conformational stability of the 
wild-type and mutant models. Those stable parts of each trajectory which spanned at least 40 ns were used for 
further analysis with cpptraj, including computing average structures, hydrogen bond (HB) and hydrophobic 
interaction (HI) occupancies and secondary structure content. The average structures have been evaluated with 
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the Protein interfaces, surfaces and assemblies service PISA at the European Bioinformatics Institute (http://www.
ebi.ac.uk/pdbe/prot_int/pistart.html)73,74. The HB occupancies were calculated based on the following limits: 
3.2 Å for the donor-acceptor distance and 120° for the donor-hydrogen-acceptor bond angle. The HI occupancies 
were calculated for the hydrophobic contacts between two residues in the range of 3.5–5.5 Å.
Essential dynamics (ED). In general, the method is based on the construction of the covariance matrix of 
coordinate fluctuations, which is diagonalized in order to obtain the eigenvectors and eigenvalues that represent 
the concerted motion in the system. While the eigenvectors indicate the directions of motion, the corresponding 
eigenvalues reflect the amplitudes of motion along those directions. The trajectories have been sampled uniformly 
either to obtain 2,500 frames for each individual analysis (PCA-1 and PCA-2) or every 50th frame to obtain 4,406 
frames for combined analysis (PCA-3). In the latter analysis, all possible distances between four central α-helices 
were measured. The objective was to reduce the number of features describing those distances to 2. The helices 
were defined as follows: 609–639 (A1) and 692–715 (A2) from subunit A and 1523–1552 (B1) and 1605–1628 
(B2) from subunit B. All analyses were carried out with either pyPCAZIP, a python-based reimplementation of 
the PCAZIP package (PCA-1 and PCA-2)75 or scikit-learn Python package (PCA-3)76. The plots of concerted 
motions were prepared with the help of cpptraj and the Normal Mode Wizard VMD plugin77,78 and rendered with 
POV-Ray 3.6 (PCA-1 and PCA-2)79.
Ethics Statement. Written informed consent was obtained from all patients for muscle biopsy analyses 
as well as for genetic testing, according to the Declaration of Helsinki. The study was approved by the Ethics 
Committee of the Warsaw Medical University (Warsaw, Poland) in compliance with national legislation and with 
the Code of Ethical Principles for Medical Research Involving Human Subjects of the World Medical Association.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on a reasonable request.
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